secwatch / observer

8-K filed February 26, 2025, 6:59 PM ET ticker VERA CIK 0001831828

earnings confidence high sentiment neutral materiality 0.55

Vera Therapeutics reports 2024 net loss $152.1M; atacicept Phase 3 primary endpoint due Q2 2025

Vera Therapeutics, Inc.

2024-FY EPS reported -$2.75

Net loss of $152.1M ($2.75 diluted EPS) vs $96.0M ($2.25) in 2023; cash burn $134.7M operating.
Cash and equivalents $640.9M as of Dec 31, 2024; sufficient through potential 2026 commercial launch.
Phase 3 ORIGIN trial primary endpoint expected Q2 2025; BLA submission for atacicept planned H2 2025.
Expanded pipeline: atacicept in PMN, FSGS, MCD; acquired next-gen fusion protein VT-109 in 2024.
FDA Breakthrough Therapy Designation granted for atacicept in IgAN during 2024.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-027337
form_type: 8-K
ticker: VERA
cik: 0001831828
company_name: Vera Therapeutics, Inc.
filed_at: 2025-02-26T23:59:59+00:00
discovered_at: 2026-05-14T18:03:05.149465+00:00
generated_at: 2026-05-26T03:51:33.981172+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-027337
json_url: https://secwatch.observer/filing/0000950170-25-027337.json
markdown_url: https://secwatch.observer/filing/0000950170-25-027337.md
text_url: https://secwatch.observer/filing/0000950170-25-027337.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1831828/000095017025027337/0000950170-25-027337-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1831828/000095017025027337/vera-20250226.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

IVF

INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M

INVO Fertility, Inc. June 2, 2026, 8:40 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

POLA

Polar Power Q1 net loss narrows 86% to $178K; gross margin expands to 65.7%

Polar Power, Inc. June 2, 2026, 8:30 AM ET earnings Items 2.02, 7.01, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

CTRN

Citi Trends Q1 sales up 14.4% to $230.9M; adjusted EBITDA doubles to $13.9M

Citi Trends Inc June 2, 2026, 6:58 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

DAVEY TREE EXPERT CO

Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M

DAVEY TREE EXPERT CO June 1, 2026, 1:50 PM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

BKE

Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M

BUCKLE INC May 29, 2026, 3:38 PM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

HIND

Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis

Vyome Holdings, Inc May 29, 2026, 8:42 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

PKE

Park Aerospace Q4 sales up 43% to $24.2M; EPS $0.19 vs $0.06 YoY; full-year net earnings double to $11.3M

PARK AEROSPACE CORP May 28, 2026, 4:29 PM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

GAP

Gap Inc. Q1 net sales up 1% to $3.5B; adj. EPS $0.38; raises full-year EPS outlook

GAP INC May 28, 2026, 4:16 PM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0000950170-25-027337

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.